HSP60与支气管哮喘相关性的探讨  

HSP60 and bronchial asthma

作　　者：龚素波[1] 李坑[1] 徐礼[1] 马礼兵[1] 张莉[1] 欧阳若芸[1] 向旭东[1] 

机构地区：[1]中南大学湘雅二医院呼吸内科,长沙410011

出　　处：《中华哮喘杂志（电子版）》2013年第2期126-130,共5页Chinese Journal of Asthma(Electronic Version)

摘　　要：支气管哮喘(简称哮喘)是以气道高反应为特征的慢性气道炎症。目前哮喘的治疗局限在控制临床症状上,因此应用更广泛的治疗手段亟待大家去探索。CD4+T淋巴细胞在哮喘的气道炎症、黏液产生、气道高反应性中起了极其重要的作用。近年来有研究发现热休克蛋白60(heat shock protein 60,HSP60)能够介导CD4+T淋巴细胞的分化,提示HSP60可能成为治疗哮喘的新靶点,尤其是重症哮喘和难治性哮喘。本文旨在就目前的关于HSP60和哮喘关系的研究作一综述。Bronchial asthma ( asthma ) is a chronic and complex airway inflammatory disease characterized by airway hyper-responsiveness.Current asthma therapies are limited to specific disease manifestations , highlighting the importance of developing treatments with broader treatment applications. CD4+ T lymphocytes , which produce a characteristic repertoire of cytokines , play a critical role in the development of airway inflammation , mucus production and airway hyper-responsiveness in asthma. Recently , it has been demonstrated that heat shock protein 60 ( HSP60 ) could mediate CD4 + T lymphocyte differentiation , suggesting that HSP60can be targeted in the development of novel anti-asthma medications , especially for the treatment of severe disease or refractory patients.This review summarizes the current knowledge regarding the relationship between HSP60and asthma.

关 键 词：热休克蛋白60 CD4+T淋巴细胞 支气管哮喘 

分 类 号：R24[医药卫生—中医临床基础] R97[医药卫生—中医学]